Loading stock data…
NPCE
$15.91-0.05 (-0.28%)
Market OpenUpdated 1:10 PM EDT
NeuroPace, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NeuroPace, Inc. in the Healthcare sector is trading at $15.91 with a market capitalization of $541M. Wall Street consensus targets $20.00 (8 analysts), implying a +25.7% move over the next 12 months. The stock is currently 19% below its 52-week high of $19.60, remaining 13.0% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +25.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $22.07M↓ | $26.59M↓ | $27.35M↑ | $23.52M↑ | $22.52M |
| Gross Profit | $18.05M↓ | $20.58M↓ | $21.17M↑ | $18.13M↑ | $17.34M |
| Operating Income | -$5.57M↓ | -$1.77M↑ | -$2.60M↑ | -$6.82M↓ | -$5.15M |
| Net Income | -$6.69M↓ | -$2.73M↑ | -$3.50M↑ | -$8.65M↓ | -$6.59M |
Peer Comparison
JNJUNHPFE
Fundamentals
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant fo...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$541.41M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.93
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-149.20%
Volume
Today's trading volume
36,016
Recent News
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now
NPCE rides strong RNS adoption and AI tools nearing FDA review, with a mid-2026 IGE decision offering upside despite near-term losses.
How The NeuroPace (NPCE) Investment Story Is Shifting Without A New Analyst Price Target
NeuroPace enters this update cycle with its price target unchanged, reflecting a steady view from covering analysts. Instead of reacting to new commentary, you are looking at a story where the official target remains in place while the underlying thesis may still be evolving. Read on to see how to track those shifts and build your own view as fresh information comes through. Stay updated as the Fair Value for NeuroPace shifts by adding it to your watchlist or portfolio. Alternatively, explore...
Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift?
NeuroPace exits DIXI, doubles down on RNS as Q1 narrows losses and lifts 2026 guidance, Medicare and pricing actions support margins.
NPCE Explains How NeuroPace's RNS System Makes Money
NeuroPace tightens focus on its RNS epilepsy implant, exits DIXI distribution and pushes AI + cloud workflow tools as 2026 revenue guidance rises.
NeuroPace NPCE and the Next Wave of AI-Driven Epilepsy Care
NPCE bets on AI ECoG Assistant and cloud upgrades as it refocuses on RNS, while IGE label review and coverage timing loom.